Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 15/20 | 0.58 |
| ▸ | MAPK12 | P53778 | 15/20 | 0.58 |
| ▸ | MAPK11 | Q15759 | 15/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 15/20 | 0.58 |
| ▸ | GCGR | P47871 | 14/20 | 0.58 |
| ▸ | MAPK9 | P45984 | 4/20 | 0.51 |
| ▸ | RAF1 | P04049 | 2/20 | 0.51 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.48 |
| ▸ | FRK | P42685 | 3/20 | 0.48 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.48 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.48 |
| ▸ | GSK3B | P49841 | 3/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.48 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.48 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 8/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4553347 | 0.87 | MAPK14 (0.76) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL4586521 | 0.82 | MAPK14 (0.51) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL4584932 | 0.79 | MAPK14 (0.46) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL4975933 | 0.77 | MAPK14 (0.85) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL4553291 | 0.76 | MAPK14 (0.72) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL4554967 | 0.76 | MAPK14 (0.62) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL7209162 | 0.74 | MAPK14 (0.55) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL4552049 | 0.74 | ALOX5 (0.73) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL4553727 | 0.74 | MAPK14 (0.59) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL2648992 | 0.74 | MAPK14 (1.00) | MAPK13MAPK12MAPK11MAPK14GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0943616-B1 | Substituted imidazole derivatives and their use as cytokine inhibitors | SMITHKLINE BEECHAM CORP (US) | 2005-05-04 | — | — | EP | claimed |
| US-6288089-B1 | ADMINISTERING A COMPOSITION OF PYRIDYL IMIDAZOLE COMPOUNDS TO TREAT PARKINSON'S DISEASE, HUNTINGTON'S DISEASE, ALZHEIMER'S DISEASE, AND AMYOTOPHIC LATERAL SCLEROSIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2001-09-11 | — | — | US | claimed |
| EP-0943616-A1 | Substituted imidazole derivatives and their use as cytokine inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1999-09-22 | — | — | EP | claimed |
| EP-1487436-A4 | COMBINATION THERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS | SIGNAL PHARM INC (US) | 2009-06-03 | — | — | EP | disclosed |
| US-7351729-B2 | JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-04-01 | — | — | US | disclosed |
| US-20070149571-A1 | Combination therapy for treating or managing acute myelocytic leukemia | SIGNAL PHARMACEUTICALS, LLC | 2007-06-28 | — | — | US | disclosed |
| EP-0943616-B1 | Substituted imidazole derivatives and their use as cytokine inhibitors | SMITHKLINE BEECHAM CORP (US) | 2005-05-04 | — | — | EP | disclosed |
| EP-1487436-A1 | COMBINATION THERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS | Signal Pharmaceuticals, Inc. (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20040067953-A1 | Combination therapy for treating, preventing or managing proliferative disorders and cancers | SIGNAL PHARMACEUTICALS, LLC | 2004-04-08 | — | — | US | disclosed |
| US-6645989-B2 | Antiinflammatory agents | SMITHKLINE BEECHAM CORPORATION | 2003-11-11 | — | — | US | disclosed |
| WO-2003075917-A1 | COMBINATION THERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-09-18 | — | — | WO | disclosed |
| US-6288089-B1 | ADMINISTERING A COMPOSITION OF PYRIDYL IMIDAZOLE COMPOUNDS TO TREAT PARKINSON'S DISEASE, HUNTINGTON'S DISEASE, ALZHEIMER'S DISEASE, AND AMYOTOPHIC LATERAL SCLEROSIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2001-09-11 | — | — | US | disclosed |
| US-6268370-B1 | CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION | 2001-07-31 | — | — | US | disclosed |
| US-6235760-B1 | CENTRAL NERVOUS SYSTEM DISORDERS; ANTIINFLAMMATORY AGENTS | SMITHKLINE BEECHAM CORPORATION | 2001-05-22 | — | — | US | disclosed |
| EP-0943616-A1 | Substituted imidazole derivatives and their use as cytokine inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1999-09-22 | — | — | EP | disclosed |
| US-5916891-A | CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1999-06-29 | — | — | US | disclosed |
| US-5686455-A | Imidazole derivatives and their use as cytokine inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1997-11-11 | — | — | US | disclosed |
| US-5656644-A | CYTOKINE SUPPRESSORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-08-12 | — | — | US | disclosed |
| EP-0623126-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-11-09 | — | — | EP | disclosed |
| WO-1993014081-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149571-A1 | Combination therapy for treating or managing acute myelocytic leukemia | MCL1, ATF1, MAP3K5 | MAPK13 66/4885MAPK12 59/4885MAPK11 71/4885 |
| US-20040067953-A1 | Combination therapy for treating, preventing or managing proliferative disorders and cancers | MAP3K1, MAP3K2, MAP2K2 | MAPK13 54/4885MAPK12 56/4885MAPK11 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.